TNFRSF4 and neoplasm: Campos Carrascosa, van Beek et al. used lymphocytes from resected tumor, tumor-free (TF) tissue and peripheral blood mononuclear cells (PBMC) of 96 patients with hepatocellular and colorectal cancers to test the in vitro T-cell agonistic activity of OX40-targeting antibodies (Campos Carrascosa et al., 2020).